Q-linea AB (publ), a company listed on Nasdaq Stockholm that develops and delivers innovative solutions for the diagnosis of infectious diseases, has carried out a directed issue of shares raising the company gross proceeds of SEK 270 million.
The subscription price has been determined through an accelerated book building to SEK 67.50 per share, which corresponds to a discount of approximately 2.5 percent in relation to the closing price on Nasdaq Stockholm on 2 June 2020. A number of Swedish and international institutional investors and sector specialist investors participated in the directed issue.
Lindahl’s team consisted of Mattias Prage (responsible partner), Emelie Carmhagen Wernoff, Helena Lindbäck and Amanda Sjöberg.
